Anti-GLTD2/ GLTPD2 functional antibody

Anti-GLTD2/ GLTPD2 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to GLTPD2/GLTPD2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0245-Ab-1/ GM-Tg-hg-SE0245-Ab-2Anti-Human GLTPD2 monoclonal antibodyHuman
GM-Tg-rg-SE0245-Ab-1/ GM-Tg-rg-SE0245-Ab-2Anti-Rat GLTPD2 monoclonal antibodyRat
GM-Tg-mg-SE0245-Ab-1/ GM-Tg-mg-SE0245-Ab-2Anti-Mouse GLTPD2 monoclonal antibodyMouse
GM-Tg-cynog-SE0245-Ab-1/ GM-Tg-cynog-SE0245-Ab-2Anti-Cynomolgus/ Rhesus macaque GLTPD2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0245-Ab-1/ GM-Tg-felg-SE0245-Ab-2Anti-Feline GLTPD2 monoclonal antibodyFeline
GM-Tg-cang-SE0245-Ab-1/ GM-Tg-cang-SE0245-Ab-2Anti-Canine GLTPD2 monoclonal antibodyCanine
GM-Tg-bovg-SE0245-Ab-1/ GM-Tg-bovg-SE0245-Ab-2Anti-Bovine GLTPD2 monoclonal antibodyBovine
GM-Tg-equg-SE0245-Ab-1/ GM-Tg-equg-SE0245-Ab-2Anti-Equine GLTPD2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0245-Ab-1/ GM-Tg-hg-SE0245-Ab-2; GM-Tg-rg-SE0245-Ab-1/ GM-Tg-rg-SE0245-Ab-2;
GM-Tg-mg-SE0245-Ab-1/ GM-Tg-mg-SE0245-Ab-2; GM-Tg-cynog-SE0245-Ab-1/ GM-Tg-cynog-SE0245-Ab-2;
GM-Tg-felg-SE0245-Ab-1/ GM-Tg-felg-SE0245-Ab-2; GM-Tg-cang-SE0245-Ab-1/ GM-Tg-cang-SE0245-Ab-2;
GM-Tg-bovg-SE0245-Ab-1/ GM-Tg-bovg-SE0245-Ab-2; GM-Tg-equg-SE0245-Ab-1/ GM-Tg-equg-SE0245-Ab-2
Products NameAnti-GLTPD2 monoclonal antibody
Formatmab
Target NameGLTPD2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GLTPD2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0245-Ag-1Recombinant multi-species GLTD2/ GLTPD2 protein


    Target information

    Target IDGM-SE0245
    Target NameGLTPD2
    Gene ID388323,216871,497943,709758,607478,105261159,100300004,100072874
    Gene Symbol and SynonymsC730027E14Rik,GLTPD2,RGD1560459
    Uniprot AccessionA6NH11
    Uniprot Entry NameGLTD2_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000182327
    Target ClassificationN/A

    The target: GLTPD2, gene name: GLTPD2, also named as . Predicted to enable ceramide 1-phosphate binding activity and ceramide 1-phosphate transfer activity. Predicted to be involved in ceramide transport and intermembrane lipid transfer. Predicted to be active in cytosol and membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.